


Online Resources for Urticaria Patient Education



UCARE (Urticaria Centers of Reference and Excellence)

<https://ga2len-ucare.com/centers/>

UCARE is a global network of specialized centers dedicated to the diagnosis and treatment of urticaria. The website provides information about the UCARE network, including the centers that are part of it, as well as resources for healthcare professionals and patients.

Allergy & Asthma Network

<https://allergyasthmanetwork.org/>

The Allergy & Asthma Network is a leading patient education resource for allergy and asthma information.

Chronic Urticaria Management, Resources, and Glossary of Terms page

<https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/management-and-resources/>

This page on the Allergy & Asthma Network website offers educational resources on chronic urticaria, including video webinars and a glossary of related terms.

Chronic Idiopathic Urticaria page

<https://allergyasthmanetwork.org/health-a-z/chronic-urticaria/ciu/>

This page on the Allergy & Asthma Network website provides detailed information about chronic idiopathic urticaria, including symptoms, causes, and treatment options.

Allergy UK

<https://www.allergyuk.org>

Allergy UK is a leading patient education and advocacy organization in the United Kingdom.

Urticaria (Hives) and Other Skin Allergy page

<https://www.allergyuk.org/types-of-allergies/urticaria-hives-other-skin-allergy/>

This page on their website offers information on urticaria, including causes, symptoms, and treatment options.

Allergy & Anaphylaxis Australia

<https://allergyfacts.org.au/allergy-anaphylaxis/urticaria-hives>


Allergy & Anaphylaxis Australia is a non-profit organization dedicated to improving the lives of people with allergies and anaphylaxis.

Urticaria (Hives) and Angioedema page

<https://allergyfacts.org.au/>

This page on their website provides educational resources on urticaria for patients living in Australia.

Checklists for Educating Patients With Chronic Urticaria




Educating Patients on Chronic Urticaria

- Explain what chronic urticaria (CU) is and how it differs from acute urticaria
- Discuss possible causes and triggers of CU, and how they can be diagnosed with testing
- Describe available treatment options and their potential benefits and risks
- Advise patients to avoid triggers and manage stress to reduce symptoms
- Encourage patients to keep a diary of symptoms and triggers to help identify patterns and inform treatment decisions
- Emphasize the importance of long-term management of CU and regular follow-up appointments
- Recommend reputable online resources for patient education and support, as well as any available printed materials or local organizations for additional information or resources
- Address any questions or concerns the patient may have and encourage them to be an active participant in their treatment plan
- Educate patients about the possibility of participating in clinical trials and discuss the potential benefits and risks of enrolling in one, if applicable

Educating Patients With Chronic Urticaria on Clinical Trials

- Explain the purpose and benefits of clinical trials for CU
- Provide a clear and concise overview of the clinical trial process, including the different phases of the trials and what is involved with participation
- Discuss the potential benefits and risks of participating in a clinical trial for CU
- Provide information on the specific clinical trials available for CU, including the treatment approach, how the treatment works, and eligibility criteria
- Discuss any potential costs associated with participating in a clinical trial for CU, including travel expenses and insurance coverage
- Encourage patients to ask questions and express any concerns they may have about participating in a clinical trial
- Provide patients with reputable resources for additional information on clinical trials for CU

Selected Clinical Trials of Investigational Treatments of Chronic Urticaria



Intervention	Phase	Patient Population	ClinicalTrials.gov Identifier (Trial Name)
Dupilumab every 4 or every 2 weeks with or without an initial loading dose based on weight and age	3	Patients aged ≥ 2 years to < 12 years with uncontrolled CSU or CICU	NCT05526521 (LIBERTY-CSU/ CINDU CUPIDKids)
Remibrutinib oral twice daily vs placebo	3	Adolescents aged 12- < 18 years with CSU and inadequate response to H ₁ -antihistamine	NCT05513001 ^a
Barzolvomab (75 mg, 150 mg, or 300 mg) vs placebo	2	Male and female adults (aged ≥ 18 years) with a ≥ 6 -month diagnosis of CSU despite stable second-generation non-sedating H ₁ -antihistamine treatment	NCT05368285
Barzolvomab (150 mg or 300 mg) vs placebo	2	Male and female adults (aged ≥ 18 years) with a ≥ 6 month diagnosis of CICU despite stable second-generation non-sedating H ₁ -antihistamine treatment	NCT05405660
Lirentelimab (300 mg every 2 weeks) vs placebo	2	Male and female adults (aged ≥ 18 years) with moderate-severe CSU refractory to H ₁ -antihistamine treatment; CSU diagnosis for ≥ 6 months	NCT05528861 (MAVERICK)

CICU: cold-induced chronic urticaria; CSU: chronic spontaneous urticaria; CU: chronic urticaria.

^aNot recruiting as of April 2023.